BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Amini Kadijani A, Asadzadeh Aghdaei H, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Nguyen VQ, Mays JL, Reza Zali M. Transmembrane TNF-α Density, but not Soluble TNF-α Level, is Associated with Primary Response to Infliximab in Inflammatory Bowel Disease. Clin Transl Gastroenterol 2017;8:e117. [PMID: 28914262 DOI: 10.1038/ctg.2017.44] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Jacobson EC, Jain L, Vickers MH, Olins AL, Olins DE, Perry JK, O'Sullivan JM. TNF-α Differentially Regulates Cell Cycle Genes in Promyelocytic and Granulocytic HL-60/S4 Cells. G3 (Bethesda) 2019;9:2775-86. [PMID: 31263060 DOI: 10.1534/g3.119.400361] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
2 Aghdaei HA, Kadijani AA, Sorrentino D, Mirzaei A, Shahrokh S, Balaii H, Geraci M, Zali MR. An increased Bax/Bcl-2 ratio in circulating inflammatory cells predicts primary response to infliximab in inflammatory bowel disease patients. United European Gastroenterol J. 2018;6:1074-1081. [PMID: 30228896 DOI: 10.1177/2050640618774637] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
3 Sutcliffe M, Radley G, Barton A. Personalized medicine in rheumatic diseases: how close are we to being able to use genetic biomarkers to predict response to TNF inhibitors? Expert Review of Clinical Immunology 2020;16:389-96. [DOI: 10.1080/1744666x.2020.1740594] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Hong ST, Koh B, Choi SJ, Yoon E, Pyo MC, Choi JW, Kim MS, Lee EJ, Paik KC, Han MS, Chun HJ, Heo JN, Kim ES, Cho BR. Two-Photon Probe for TNF-α. Assessment of the Transmembrane TNF-α Level in Human Colon Tissue by Two-Photon Microscopy. Anal Chem 2019;91:15769-76. [PMID: 31663332 DOI: 10.1021/acs.analchem.9b04036] [Reference Citation Analysis]
5 Giachero F, Jenke A, Zilbauer M. Improving prediction of disease outcome for inflammatory bowel disease: progress through systems medicine. Expert Rev Clin Immunol 2021;17:871-81. [PMID: 34142929 DOI: 10.1080/1744666X.2021.1945442] [Reference Citation Analysis]
6 Naviglio S, Giuffrida P, Stocco G, Lenti MV, Ventura A, Corazza GR, Di Sabatino A. How to predict response to anti-tumour necrosis factor agents in inflammatory bowel disease. Expert Review of Gastroenterology & Hepatology 2018;12:797-810. [DOI: 10.1080/17474124.2018.1494573] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
7 Jessen B, Rodriguez-Sillke Y, Sonnenberg E, Schumann M, Kruglov A, Freise I, Schmidt F, Maul J, Kühl AA, Glauben R, Lissner D, Siegmund B. Level of Tumor Necrosis Factor Production by Stimulated Blood Mononuclear Cells Can Be Used to Predict Response of Patients With Inflammatory Bowel Diseases to Infliximab. Clin Gastroenterol Hepatol 2021;19:721-731.e1. [PMID: 32272247 DOI: 10.1016/j.cgh.2020.03.066] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Safa A, Bagherifard A, Hadi Al-Baseesee H, Amini Kadijani A, Yahyazadeh H, Azizi M, Akbari A, Mirzaei A. Serum Calprotectin as a Blood-Based Biomarker for Monitoring Knee Osteoarthritis at Early but Not Late Stages. Cartilage 2020;:1947603520961161. [PMID: 33000650 DOI: 10.1177/1947603520961161] [Reference Citation Analysis]
9 Diallo K, Simons N, Sayegh S, Baron M, Degboé Y, Boyer JF, Kruglov A, Nedospasov S, Novarino J, Aloulou M, Fazilleau N, Constantin A, Cantagrel A, Davignon JL, Rauwel B. Evidence for tmTNF reverse signaling in vivo: Implications for an arginase-1-mediated therapeutic effect of TNF inhibitors during inflammation. iScience 2021;24:102331. [PMID: 33889824 DOI: 10.1016/j.isci.2021.102331] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Azramezani Kopi T, Amini Kadijani A, Parsian H, Shahrokh S, Asadzadeh Aghdaei H, Mirzaei A, Balaii H, Zali MR. The value of mRNA expression of S100A8 and S100A9 as blood-based biomarkers of inflammatory bowel disease. Arab J Gastroenterol 2019;20:135-40. [PMID: 31563476 DOI: 10.1016/j.ajg.2019.07.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
11 Gisbert JP, Chaparro M. Predictors of Primary Response to Biologic Treatment [Anti-TNF, Vedolizumab, and Ustekinumab] in Patients With Inflammatory Bowel Disease: From Basic Science to Clinical Practice. Journal of Crohn's and Colitis 2020;14:694-709. [DOI: 10.1093/ecco-jcc/jjz195] [Cited by in Crossref: 38] [Cited by in F6Publishing: 31] [Article Influence: 12.7] [Reference Citation Analysis]
12 Giuffrida P, Di Sabatino A. Targeting T cells in inflammatory bowel disease. Pharmacol Res. 2020;159:105040. [PMID: 32585338 DOI: 10.1016/j.phrs.2020.105040] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]